Literature DB >> 31949715

miR-26b inhibits total neurite outgrowth, promotes cells apoptosis and downregulates neprilysin in Alzheimer's disease.

Tingting Chu1,2, Yongwei Shu2, Yang Qu2, Shasha Gao3, Liming Zhang1.   

Abstract

This study aimed to investigate the effect of miR-26b expression on neurites outgrowth and cells apoptosis in PC12 cellular model of Alzheimer's disease (AD). PC12 cells were stimulated by nerve growth factor and insulted by Aβ1-42 to establish PC12 cellular AD model. Methyl thiazolyl tetrazolium (MTT) assay was then used to detect cells viability. Blank mimic, miR-26b mimic, blank inhibitor and miR-26b inhibitor plasmids were transferred into PC12 cellular AD models as NC1-mimic, miR-26b mimic, NC2-inhibitor and miR-26b inhibitor groups respectively. mRNA level, protein level, total neurite outgrowth and cells apoptosis were determined by qPCR, western blot, microscope and Hoechst/PI, respectively. MTT reduction rate was decreased in Aβ1-42 insult group compared to control group (P<0.001). After plasmids transfection, the total neuritis growth was found to be reduced in miR-26b mimic group compared with NC1-mimic group (P<0.05) while was elevated in miR-26b inhibitor group compared with NC2-inhibitor group (P<0.01). As to cells apoptosis, the percentage of apoptosis cells was increased in miR-26b mimic group than NC1-mimic group (P<0.05), and was decreased in miR-26b inhibitor group than NC2-inhibitor group (P<0.05). In addition, neprilysin (NEP) protein and mRNA expressions were decreased in miR-26b mimic group than NC1-mimic group and was increased in miR-26b inhibitor group than NC2-inhibitor group. However, protein or mRNA expression of EIF2S1 and αTTP was not affected by miR-26b. In conclusion, miR-26b inhibits neurite outgrowth, induces cells apoptosis and downregulates NEP expression in PC12 cellular AD model. IJCEP
Copyright © 2018.

Entities:  

Keywords:  Alzheimer’s disease; PC12; apoptosis; miR-26b; neurite outgrowth

Year:  2018        PMID: 31949715      PMCID: PMC6962878     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  27 in total

1.  microRNA-34c is a novel target to treat dementias.

Authors:  Athanasios Zovoilis; Hope Y Agbemenyah; Roberto C Agis-Balboa; Roman M Stilling; Dieter Edbauer; Pooja Rao; Laurent Farinelli; Ivana Delalle; Andrea Schmitt; Peter Falkai; Sanaz Bahari-Javan; Susanne Burkhardt; Farahnaz Sananbenesi; Andre Fischer
Journal:  EMBO J       Date:  2011-09-23       Impact factor: 11.598

2.  MicroRNA-195 downregulates Alzheimer's disease amyloid-β production by targeting BACE1.

Authors:  Hong-Can Zhu; Li-Mei Wang; Miao Wang; Bo Song; Song Tan; Jun-Fang Teng; Dong-Xiao Duan
Journal:  Brain Res Bull       Date:  2012-06-19       Impact factor: 4.077

3.  MiR-26b, upregulated in Alzheimer's disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons.

Authors:  Sabrina Absalon; Dawn M Kochanek; Venkatesan Raghavan; Anna M Krichevsky
Journal:  J Neurosci       Date:  2013-09-11       Impact factor: 6.167

4.  Altered expression of microRNAs in the neuronal differentiation of human Wharton's Jelly mesenchymal stem cells.

Authors:  Hong Zhuang; Rong Zhang; Shujie Zhang; Qinmeng Shu; Dan Zhang; Gezhi Xu
Journal:  Neurosci Lett       Date:  2015-06-03       Impact factor: 3.046

5.  Intronic miR-26b controls neuronal differentiation by repressing its host transcript, ctdsp2.

Authors:  Holger Dill; Bastian Linder; Alexander Fehr; Utz Fischer
Journal:  Genes Dev       Date:  2012-01-01       Impact factor: 11.361

6.  Clearance of extracellular and cell-associated amyloid beta peptide through viral expression of neprilysin in primary neurons.

Authors:  E Hama; K Shirotani; H Masumoto; Y Sekine-Aizawa; H Aizawa; T C Saido
Journal:  J Biochem       Date:  2001-12       Impact factor: 3.387

7.  Messenger RNA-based therapeutics for brain diseases: An animal study for augmenting clearance of beta-amyloid by intracerebral administration of neprilysin mRNA loaded in polyplex nanomicelles.

Authors:  Chin-Yu Lin; Federico Perche; Masaru Ikegami; Satoshi Uchida; Kazunori Kataoka; Keiji Itaka
Journal:  J Control Release       Date:  2016-06-06       Impact factor: 9.776

8.  Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease.

Authors:  Jonathan Spiegel; Elizabeth Pirraglia; Ricardo S Osorio; Lidia Glodzik; Yi Li; Wai Tsui; Leslie A Saint Louis; Catherine Randall; Tracy Butler; Jinfeng Xu; Raymond P Zinkowski; Henrik Zetterberg; Juan Fortea; Silvia Fossati; Thomas Wisniewski; Peter Davies; Kaj Blennow; Mony J de Leon
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

9.  Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice.

Authors:  Nobuhisa Iwata; Misaki Sekiguchi; Yoshino Hattori; Akane Takahashi; Masashi Asai; Bin Ji; Makoto Higuchi; Matthias Staufenbiel; Shin-ichi Muramatsu; Takaomi C Saido
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

10.  Genome-Wide Profiling of miRNA and mRNA Expression in Alzheimer's Disease.

Authors:  Wan-Sheng Chang; Yong-Hong Wang; Xiao-Tun Zhu; Chuan-Jie Wu
Journal:  Med Sci Monit       Date:  2017-06-04
View more
  3 in total

Review 1.  MicroRNAs in the pathophysiology of Alzheimer's disease and Parkinson's disease: an overview.

Authors:  Mohammad Rafi Khezri; Keyvan Yousefi; Naime Majidi Zolbanin; Morteza Ghasemnejad-Berenji
Journal:  Mol Neurobiol       Date:  2022-01-09       Impact factor: 5.590

Review 2.  MicroRNA Alteration, Application as Biomarkers, and Therapeutic Approaches in Neurodegenerative Diseases.

Authors:  T P Nhung Nguyen; Mandeep Kumar; Ernesto Fedele; Giambattista Bonanno; Tiziana Bonifacino
Journal:  Int J Mol Sci       Date:  2022-04-25       Impact factor: 6.208

Review 3.  microRNAs as Early Biomarkers of Alzheimer's Disease: A Synaptic Perspective.

Authors:  Dolores Siedlecki-Wullich; Alfredo J Miñano-Molina; José Rodríguez-Álvarez
Journal:  Cells       Date:  2021-01-09       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.